Abstract
Sixty three patients aged 27-66 years (median 52) were allografted from HLA-matched sibling (n = 47), 10 of 10 allele-matched unrelated (n = 19), or one-antigen/allele-mismatched (n = 7) donors aged 24-69 years (median 46) after a conditioning regimen comprising 100mg/m2 melphalan. Cyclophosphamide (50mg/kg) was also administered to patients who had not been autografted previously. Cyclosporine or tacrolimus, and mycophenolate mofetil were administered to prevent graft-versus-host disease (GVHD). The 2-year cumulative incidences of relapse and TRM were 55 and 24% respectively, and 2-year probabilities of overall survival (OS) and disease-free survival (DFS) were 36 and 21%, respectively. Poor performance status, donor age >45 years and elevated lactate dehydrogenase (LDH) increased the risk of treatment-related mortality (TRM), refractory disease and donor age >45 years increased the risk of relapse, and OS and DFS were adversely influenced by refractory disease, poor performance status, increased LDH, and donor age >45 years. Our data suggest that younger donor age is associated with better outcome after sub-myeloablative allogeneic hematopoietic stem cell transplantation (HSCT) for hematologic malignancies due to lower TRM and relapse. This finding raises the question of whether a young 10-allele-matched unrelated donor is superior to an older matched sibling donor in patients where the clinical situation permits a choice between such donors.
Original language | English (US) |
---|---|
Pages (from-to) | 95-100 |
Number of pages | 6 |
Journal | Bone Marrow Transplantation |
Volume | 38 |
Issue number | 2 |
DOIs | |
State | Published - Jul 2 2006 |
Keywords
- Age
- Allograft
- Relapse
ASJC Scopus subject areas
- Hematology
- Transplantation